Biophysical Characterization of Endotoxin Inactivation by NK-2, an Antimicrobial Peptide Derived from Mammalian NK-lysin

Overview

Journal Antimicrob Agents Chemother

Publisher American Society for Microbiology

Specialty Pharmacology

Date 2004 Apr 24

PMID 15105110

Citations 34

Authors

Jorg Andra

Michel H J Koch

Rainer Bartels

Klaus Brandenburg

Affiliations

Soon will be listed here.

Abstract

NK-2, a membrane-acting antimicrobial peptide, was derived from the cationic core region of porcine NK-lysin and consists of 27 amino acid residues. It adopts an amphipathic, alpha-helical secondary structure and has been shown to interact specifically with membranes of negatively charged lipids. We therefore investigated the interaction of NK-2 with lipopolysaccharide (LPS), the main, highly anionic component of the outer leaflet of the outer membrane of gram-negative bacteria, by means of biophysical and biological assays. As model organisms and a source of LPS, we used Salmonella enterica strains with various lengths of the LPS carbohydrate moiety, including smooth LPS, rough LPS, and deep rough LPS (LPS Re) mutant strains. NK-2 binds to LPS Re with a high affinity and induces a change in the endotoxin-lipid A aggregate structure from a cubic or unilamellar structure to a multilamellar one. This structural change, in concert with a significant overcompensation of the negative charges of LPS, is thought to result in the neutralization of the endotoxic LPS activity in a cell culture system. Neutralization of LPS activity by NK-2 as well as its antibacterial activity against the various Salmonella strains strongly depends on the length of the sugar chains of LPS, with LPS Re being the most sensitive. This suggests that a hydrophobic peptide-LPS interaction is necessary for efficient neutralization of the biological activity of LPS and that the long carbohydrate chains, besides their function as a barrier for hydrophobic drugs, also serve as a trap for polycationic substances.

Citing Articles

Piggybacking on nature: exploring the multifaceted world of porcine β-defensins.

Finatto A, Meurens F, de Oliveira Costa M Vet Res. 2025; 56(1):47.

PMID: 40033445 PMC: 11877871. DOI: 10.1186/s13567-025-01465-4.

Antiviral and antibacterial peptides: Mechanisms of action.

Neghabi Hajigha M, Hajikhani B, Vaezjalali M, Kafil H, Kazemzadeh Anari R, Goudarzi M Heliyon. 2025; 10(22):e40121.

PMID: 39748995 PMC: 11693924. DOI: 10.1016/j.heliyon.2024.e40121.

Comparative Properties of Helical and Linear Amphipathicity of Peptides Composed of Arginine, Tryptophan, and Valine.

Klousnitzer J, Xiang W, Polynice V, Deslouches B Antibiotics (Basel). 2024; 13(10).

PMID: 39452220 PMC: 11504230. DOI: 10.3390/antibiotics13100954.

Interaction of Pexiganan (MSI-78)-Derived Analogues Reduces Inflammation and TLR4-Mediated Cytokine Secretion: A Comparative Study.

Cohen H, Wani N, Ben Hur D, Migliolo L, Cardoso M, Porat Z ACS Omega. 2023; 8(20):17856-17868.

PMID: 37251186 PMC: 10210221. DOI: 10.1021/acsomega.3c00850.

Chimeric Peptidomimetic Antibiotic Efficiently Neutralizes Lipopolysaccharides (LPS) and Bacteria-Induced Activation of RAW Macrophages.

Javed A, Slingerland C, Wood T, Martin N, Broere F, Weingarth M ACS Infect Dis. 2023; 9(3):518-526.

PMID: 36790385 PMC: 10012172. DOI: 10.1021/acsinfecdis.2c00518.

References

Brandenburg K, Funari S, Koch M, Seydel U . Investigation into the acyl chain packing of endotoxins and phospholipids under near physiological conditions by WAXS and FTIR spectroscopy. J Struct Biol. 1999; 128(2):175-86. DOI: 10.1006/jsbi.1999.4186. View

Shimazu R, Akashi S, Ogata H, Nagai Y, Fukudome K, Miyake K . MD-2, a molecule that confers lipopolysaccharide responsiveness on Toll-like receptor 4. J Exp Med. 1999; 189(11):1777-82. PMC: 2193086. DOI: 10.1084/jem.189.11.1777. View

Andra J, Leippe M . Candidacidal activity of shortened synthetic analogs of amoebapores and NK-lysin. Med Microbiol Immunol. 2000; 188(3):117-24. DOI: 10.1007/s004300050113. View

Blunck R, Scheel O, Muller M, Brandenburg K, Seitzer U, Seydel U . New insights into endotoxin-induced activation of macrophages: involvement of a K+ channel in transmembrane signaling. J Immunol. 2001; 166(2):1009-15. DOI: 10.4049/jimmunol.166.2.1009. View

Angus D, Lidicker J, Clermont G, Carcillo J, Pinsky M . Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med. 2001; 29(7):1303-10. DOI: 10.1097/00003246-200107000-00002. View

Brandenburg K, Jurgens G, Muller M, Fukuoka S, Koch M . Biophysical characterization of lipopolysaccharide and lipid A inactivation by lactoferrin. Biol Chem. 2001; 382(8):1215-25. DOI: 10.1515/BC.2001.152. View

Zasloff M . Antimicrobial peptides of multicellular organisms. Nature. 2002; 415(6870):389-95. DOI: 10.1038/415389a. View

Jurgens G, Muller M, Garidel P, Koch M, Nakakubo H, Blume A . Investigation into the interaction of recombinant human serum albumin with Re-lipopolysaccharide and lipid A. J Endotoxin Res. 2002; 8(2):115-26. DOI: 10.1179/096805102125000263. View

Brandenburg K, Jurgens G, Andra J, Lindner B, Koch M, Blume A . Biophysical characterization of the interaction of high-density lipoprotein (HDL) with endotoxins. Eur J Biochem. 2002; 269(23):5972-81. DOI: 10.1046/j.1432-1033.2002.03333.x. View

10.

Jacobs T, Bruhn H, Gaworski I, Fleischer B, Leippe M . NK-lysin and its shortened analog NK-2 exhibit potent activities against Trypanosoma cruzi. Antimicrob Agents Chemother. 2003; 47(2):607-13. PMC: 151766. DOI: 10.1128/AAC.47.2.607-613.2003. View

11.

Caccavo D, Pellegrino N, Altamura M, Rigon A, Amati L, Amoroso A . Antimicrobial and immunoregulatory functions of lactoferrin and its potential therapeutic application. J Endotoxin Res. 2003; 8(6):403-17. DOI: 10.1179/096805102125001000. View

12.

Schroder-Borm H, Willumeit R, Brandenburg K, Andra J . Molecular basis for membrane selectivity of NK-2, a potent peptide antibiotic derived from NK-lysin. Biochim Biophys Acta. 2003; 1612(2):164-71. DOI: 10.1016/s0005-2736(03)00115-9. View

13.

Bruhn H, Riekens B, Berninghausen O, Leippe M . Amoebapores and NK-lysin, members of a class of structurally distinct antimicrobial and cytolytic peptides from protozoa and mammals: a comparative functional analysis. Biochem J. 2003; 375(Pt 3):737-44. PMC: 1223731. DOI: 10.1042/BJ20030250. View

14.

Brandenburg K, Andra J, Muller M, Koch M, Garidel P . Physicochemical properties of bacterial glycopolymers in relation to bioactivity. Carbohydr Res. 2003; 338(23):2477-89. DOI: 10.1016/j.carres.2003.08.008. View

15.

Galanos C, LUDERITZ O, Westphal O . A new method for the extraction of R lipopolysaccharides. Eur J Biochem. 1969; 9(2):245-9. DOI: 10.1111/j.1432-1033.1969.tb00601.x. View

16.

Boman H, Paul K, Rasmuson Jr T . Insect immunity. I. Characteristics of an inducible cell-free antibacterial reaction in hemolymph of Samia cynthia pupae. Infect Immun. 1974; 10(1):136-45. PMC: 414969. DOI: 10.1128/iai.10.1.136-145.1974. View

17.

Tobias P, Soldau K, Ulevitch R . Identification of a lipid A binding site in the acute phase reactant lipopolysaccharide binding protein. J Biol Chem. 1989; 264(18):10867-71. View

18.

Fisher Jr C, Opal S, Dhainaut J, Stephens S, Zimmerman J, Nightingale P . Influence of an anti-tumor necrosis factor monoclonal antibody on cytokine levels in patients with sepsis. The CB0006 Sepsis Syndrome Study Group. Crit Care Med. 1993; 21(3):318-27. DOI: 10.1097/00003246-199303000-00006. View

19.

Hailman E, Lichenstein H, Wurfel M, Miller D, Johnson D, Kelley M . Lipopolysaccharide (LPS)-binding protein accelerates the binding of LPS to CD14. J Exp Med. 1994; 179(1):269-77. PMC: 2191344. DOI: 10.1084/jem.179.1.269. View

20.

Larrick J, Hirata M, Balint R, Lee J, Zhong J, Wright S . Human CAP18: a novel antimicrobial lipopolysaccharide-binding protein. Infect Immun. 1995; 63(4):1291-7. PMC: 173149. DOI: 10.1128/iai.63.4.1291-1297.1995. View